Skip to main content
AmigoFish

Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight

From BioSpace · · 19 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

After two rejections, Replimune has made it across the regulatory finish line with its twice-rejected therapy for advanced melanoma. Meanwhile, the last of the major pharmas, including Eli Lilly and Novo Nordisk, reported second quarter earnings, and psychedelics made headlines once again.

Back to BioSpace · Report a problem